Myeloproliferative Neoplasms (MPN)

Latest News

One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com
Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

May 6th 2025

Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.

The results offer some of the first glimpses into real-world findings of the JAK inhibitor momelotinib, which was approved in 2023. | Image credit: mdaros - stock.adobe.com
Real-World Findings Confirm Clinical Data on Momelotinib in MF With Anemia

May 1st 2025

The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com
Cardiovascular Risk Factors Impact Outcomes in MPNs

April 21st 2025

In Charleston, West Virginia, Tracking MPN Symptoms Becomes a Priority
In Charleston, West Virginia, Tracking MPN Symptoms Becomes a Priority

January 17th 2025

Supportive Care | Image credit: Pexels photo
Kent Hospital MPN Initiative Focuses on Supportive Care

January 16th 2025

AJMC Provides Myelofibrosis Guideline Updates

Watch the series now!

AJMC Provides Myelofibrosis Guideline Updates

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo